Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. COLLABORATION AGREEMENTCollaboration Agreement • September 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. RESEARCH COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN PFIZER INC. AND MACROGENICS, INC. OCTOBER 13, 2010Research Collaboration and License Agreement • September 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations
This Research Collaboration and License Agreement (the “Agreement”) is entered into as of October 13, 2010 (the “Effective Date”), by and among Pfizer, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 500 Arcola Road, Collegeville, Pennsylvania 19426, United States (“Pfizer”) and MacroGenics, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 1500 East Gude Drive, Rockville, MD 20850 (“MacroGenics”). Pfizer and MacroGenics may each be referred to herein individually as a “Party” and collectively as the “Parties.”
FOURTH AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT by and among MACROGENICS, INC., THE FOUNDERS, and THE INVESTORS September 19, 2008Registration Rights Agreement • September 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations • Delaware
THIS FOURTH AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT, dated September 19, 2008 (this “Agreement”), is made by and among MacroGenics, Inc., a Delaware corporation (the “Company”), those parties identified as Founders on the signature page hereto (the “Founders”), the parties listed on Exhibit A hereto (the “Existing Investors”), the parties listed on Exhibit B hereto (the “Series D Investors”), and the parties executing the signature pages hereto (the “New Investors,” and collectively with the Existing Investors and the Series D Investors, the “Investors”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. OPTION FOR A LICENSE AGREEMENT BY AND BETWEEN MACROGENICS, INC. AND LES LABORATOIRES SERVIER AND INSTITUT DE RECHERCHES...License Agreement • September 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations
This Option for a License Agreement (this “Agreement”) is entered into and made effective as of the 24th day of November, 2011 (the “Effective Date”), by and between MacroGenics, Inc. a corporation organized and existing under the laws of the State of Delaware and having a principal office located at 1500 East Gude Drive Rockville, MD 20850, USA (“MacroGenics”), and Les Laboratoires Servier, a company organized and existing under the laws of France, having a principal office located at 50 rue Carnot 92284 Suresnes (“LLS”) and Institut de Recherches Servier, a company organized and existing under the laws of France, having a principal office located at 3 rue de la République – 92150 Suresnes - France (“IdRS” and LLS and IdRS hereinafter collectively referred to as “Servier”). MacroGenics and Servier are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
BI Contract No. 43032525 COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN BOEHRINGER INGELHEIM INTERNATIONAL GMBH AND MACROGENICS, INC. OCTOBER 18, 2010Collaboration and License Agreement • September 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations
INGELHEIM, Germany and ROCKVILLE, MD, USA, , 2010 — Boehringer Ingelheim and MacroGenics today jointly announced that they have entered into a global alliance to discover, develop and commercialize antibody-based therapeutics which may span multiple therapeutic areas, including immunology, oncology, respiratory, cardiometabolic and infectious diseases. These developmental drug candidates will be based on MacroGenics’ Dual-Affinity Re-Targeting (DART™) platform and will be directed against up to ten combinations of molecular targets.
OPTION FOR A LICENSE AGREEMENT BY AND BETWEEN MACROGENICS, INC. AND LES LABORATOIRES SERVIER AND INSTITUT DE RECHERCHES SERVIERLicense Agreement • September 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations
In no event shall the total of the amounts paid under this Section 9.3.2 for the *** Licensed Program and gpA33 Licensed Program exceed ***, or exceed *** for the CD 123 Licensed Program, and exceed *** in the aggregate for all of the Licensed Programs.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. FIRST AMENDMENT TO COLLABORATION AGREEMENTCollaboration Agreement • September 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations
THIS FIRST AMENDMENT TO THE COLLABORATION AGREEMENT (this “Amendment”) is made to be effective as of January 19, 2011 (the “Effective Date”), by and between MacroGenics, Inc., a Delaware corporation (the “Company”) and Green Cross Corporation, a corporation organized under the laws of Korea (“Green Cross”). Capitalized terms used in this Amendment and not defined herein shall have the meanings given to such terms in the Agreement (as defined below).
MACRO GENICS, INC. Second Amendment to Lease AgreementSecond Amendment to Lease Agreement • September 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations
This second amendment to lease agreement (“AGREEMENT”) made and entered into this 1ST day of June 2011, by and between W. M. RICKMAN CONSTRUCTION CO. LLC (“LANDLORD”) and MACRO GENICS, INC. (“TENANT”).
MACROGENICS, INC. LEASE AGREEMENTLease Agreement • September 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations
MACRO GENICS, INC. Amendment to Lease AgreementAmendment to Lease Agreement • September 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations
SUBLEASESublease • September 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations • California
THIS BUILD-TO-SUIT LEASE (“Lease”) is made and entered into as of the 20th day of April, 1995, by and between BRITANNIA DEVELOPMENTS, INC., a California corporation (“Landlord”), and TULARIK INC., a California corporation (“Tenant”).
